Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly—A Subgroup Analysis of Routine Clinical Practice Data

Table 5

Daily tapentadol PR doses over the observation period.

	Aged >65 years (n = 752)	Aged ≤65 years (n = 282)
At the start of treatment (mg)	129.8 ± 62.0	132.5 ± 64.7
2 × 50 mg	564 (75%)	204 (72.3%)
2 × 100 mg	146 (19.4%)	57 (20.2%)
≥2 × 150 mg	33 (4.4%)	16 (5.7%)
Other	9 (1.2%)	5 (1.8%)
At the end of titration (mg)	181.5 ± 92.5	195.1 ± 93.3
No data	12 (1.6%)	4 (1.4%)
At the end of observation (mg)	198.6 ± 100.7	213.4 ± 103.4
No data	16 (2.1%)	5 (1.8%)

Data are mean ± SD or number of patients (%). PR, prolonged release.